References
- Falini B, Mecucci C, Tiacci E, .; GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254–266.
- Haferlach C, Mecucci C, Schnittger S, . AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009;114:3024–3032.
- Falini B, Martelli MP, Bolli N, . Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011;117:1109–1120.
- Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology Am Soc Hematol Educ Program 2010:47–55.
- Mrózek K, Marcucci G, Paschka P, . Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431–448.
- Krönke J, Schlenk RF, Jensen KO, . Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol. 2011;29:2709–2716.
- Damm F, Heuser M, Morgan M, . Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 2011;117:4561–4568.
- Pui CH, Carroll WL, Meshinchi S, . Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29:551–565.